Global PCOS Drugs Market 2014-2018

About PCOS Drugs
PCOS, also known as Stein-Leventhal Syndrome, is one of the most common hormonal endocrine disorders in women. It is characterized by polycystic ovaries, irregular or no menstrual periods, irregular ovulation, and high levels of androgens (male hormones) in the body. The exact cause of PCOS is unknown. In PCOS, small cysts form on the ovaries, which do not produce a sufficient amount of hormone to initiate ovulation. The ovarian follicles, which are filled with fluid in preparation for ovulation, remain as cysts when ovulation does not occur. Lifestyle modifications, medication, and surgery are some of the currently available treatments for PCOS.
TechNavio's analysts forecast the Global PCOS Drugs market will grow at a CAGR of 2.65 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global PCOS Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of marketed, off-label, and generic drugs used in the treatment of PCOS.
TechNavio's report, the Global PCOS Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PCOS Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ EMEA
‧ APAC
Key Vendors
‧ Bristol Myers Squibb Co.
‧ Merck & Co. Inc.
‧ Novartis AG
‧ Sanofi SA
‧ Teva Pharmaceutical Inc.
Other Prominent Vendors

‧ AstraZeneca plc
‧ Catalysis SL
‧ Crinetics Pharmaceuticals Inc.
‧ Dexa Medica Group
‧ EffRx Inc.
‧ Neurocrine Biosciences Inc.
Market Driver
‧ Increase in Patient Population.
‧ For a full, detailed list, view our report.
Market Challenge
‧ Lack of Approved Drugs.
‧ For a full, detailed list, view our report.
Market Trend
‧ Increase in Awareness of PCOS Drugs.
‧ For a full, detailed list, view our report.
Key Questions Answered in this Report
‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Competitive Analysis of Marketed Products
08. Pipeline Snapshot
09. Rate of Incidence and Prevalence
09.1.1 Americas
09.1.2 Europe
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Vendors Analysis 2013
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Sanofi SA
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Business Segmentation
19.1.4 Revenue by Business Segmentation
19.1.5 Revenue Comparison 2012 and 2013
19.1.6 Sales by Geography
19.1.7 Business Strategy
19.1.8 Key Developments
19.1.9 SWOT Analysis
19.1.10 Strengths
19.1.11 Weakness
19.1.12 Opportunities
19.1.13 Threats
19.2 Bristol Myers Squibb Co.
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Key Product Offerings
19.2.4 Sales by Geography
19.2.5 Business Strategy
19.2.6 Key Information
19.2.7 SWOT Analysis
19.2.8 Strengths
19.2.9 Weaknesses
19.2.10 Opportunities
19.2.11 Threats
19.3 Novartis A.G.
19.3.1 Key Facts
19.3.2 Business Description
19.3.3 Business Segmentation
19.3.4 Revenue by Business Segmentation
19.3.5 Revenue Comparison 2012 and 2013
19.3.6 Sales by Geography
19.3.7 Business Strategy
19.3.8 Key Developments
19.4 SWOT Analysis
19.4.1 Strengths
19.4.2 Weaknesses
19.4.3 Opportunities
19.4.4 Threats
19.5 Teva Pharmaceutical Inc.
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation
19.5.4 Revenue by Business Segmentation
19.5.5 Revenue Comparison 2012 and 2013
19.5.6 Revenue Segmentation by Geography
19.5.7 Business Strategy
19.5.8 Key Developments
19.5.9 SWOT Analysis
19.5.10 Strengths
19.5.11 Weakness
19.5.12 Opportunities
19.5.13 Threats
19.6 Merck & Co. Inc.
19.6.1 Key Facts
19.6.2 Business Description
19.6.3 Business Segmentation
19.6.4 Revenue by Business Segmentation
19.6.5 Revenue Comparison 2012 and 2013
19.6.6 Sales by Geography
19.6.7 Business Strategy
19.6.8 Key Developments
19.6.9 SWOT Analysis
19.6.10 Strengths
19.6.11 Weaknesses
19.6.12 Opportunities
19.6.13 Threats
20. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global PCOS Drugs Market 2013-2018 (US$ million)
Exhibit 3: Global PCOS Drugs Market by Geographical Segmentation 2013
Exhibit 4: Sanofi SA: Business Segmentation
Exhibit 5: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 6: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 7: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Exhibit 8: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 9: Bristol-Myers Squibb Co.: Sales by Geographical Segmentation 2013
Exhibit 10: Novartis AG: Business Segmentation
Exhibit 11: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 12: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 13: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 14: Teva Pharmaceutical Industries Ltd.: Business Segmentation
Exhibit 15: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2013
Exhibit 16: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 17: Teva Pharmaceutical Industries Ltd.: Revenue by Geographical Segmentation 2013
Exhibit 18: Merck & Co. Inc.: Business Segmentation 2013
Exhibit 19: Merck & Co. Inc.: Revenue by Business Segmentation 2013
Exhibit 20: Merck & Co. Inc.: Revenue by Business Segmentation 2012 and 2013 (US$ billion)
Exhibit 21: Merck & Co. Inc.: Revenue by Geographical Segmentation 2013